Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 547

1.

Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator.

Mannas MP, Lee T, Forbes CM, Hong T, Bisaillon A, Gleave ME, So AI, Mayson K, Black PC.

World J Urol. 2019 Aug 27. doi: 10.1007/s00345-019-02915-3. [Epub ahead of print]

PMID:
31456016
2.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.

PMID:
31348741
3.

GnRH antagonists have direct inhibitory effects on castration-resistant prostate cancer via intracrine androgen and AR-V7 expression.

Evans CP, Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC.

Mol Cancer Ther. 2019 Jul 24. pii: molcanther.1337.2018. doi: 10.1158/1535-7163.MCT-18-1337. [Epub ahead of print]

PMID:
31341032
4.

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network.

PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.

6.

Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer.

Kretschmer A, Zhang F, Somasekharan SP, Tse C, Leachman L, Gleave A, Li B, Asmaro I, Huang T, Kotula L, Sorensen PH, Gleave ME.

Sci Rep. 2019 May 24;9(1):7826. doi: 10.1038/s41598-019-44346-5.

7.
8.

A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, McKenzie M, Tyldesley S, Goldenberg SL, Bénard F.

J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381. [Epub ahead of print]

PMID:
30979820
9.

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team.

Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206-4. doi: 10.1016/j.eururo.2019.03.020. [Epub ahead of print]

PMID:
30928160
10.

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.

Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ.

Mol Cancer Res. 2019 Jun;17(6):1235-1240. doi: 10.1158/1541-7786.MCR-18-1101. Epub 2019 Mar 27.

PMID:
30918106
11.

RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.

Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.

Eur Urol. 2019 Aug;76(2):157-166. doi: 10.1016/j.eururo.2019.03.011. Epub 2019 Mar 23.

12.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
13.

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC.

Genome Med. 2019 Feb 18;11(1):8. doi: 10.1186/s13073-019-0620-3.

14.

Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.

Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick NA, Jackson MR, Cherkasov A, Ronai ZA.

Cancer Lett. 2019 May 1;449:145-162. doi: 10.1016/j.canlet.2019.02.012. Epub 2019 Feb 14.

PMID:
30771432
15.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21.

16.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

17.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.

Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.

PMID:
30638634
18.

Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE).

Kretschmer A, Gleave ME.

Eur Urol. 2019 Apr;75(4):692-693. doi: 10.1016/j.eururo.2018.12.035. Epub 2019 Jan 5. No abstract available.

PMID:
30616949
19.

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar M, Gleave ME, Chi KN.

Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24.

PMID:
30591354
20.

Subtle Protective Roles of Clusterin in Gastric Metaplasia After Acute Oxyntic Atrophy.

Vange P, Bruland T, Munkvold B, Røyset ES, Gleave M, Bakke I.

Cell Mol Gastroenterol Hepatol. 2019;7(1):246-250.e1. doi: 10.1016/j.jcmgh.2018.09.013. Epub 2018 Sep 22. No abstract available.

21.

Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation.

Chen R, Li H, Li Y, Fazli L, Gleave M, Nappi L, Dong X.

Front Oncol. 2018 Dec 7;8:594. doi: 10.3389/fonc.2018.00594. eCollection 2018.

22.

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules.

Lee CCW, Munuganti RSN, Peacock JW, Dalal K, Jiao IZF, Shepherd A, Liu L, Tam KJ, Sedgwick CG, Bhasin S, Lee KCK, Gooding L, Vanderkruk B, Tombe T, Gong Y, Gleave ME, Cherkasov A, Ong CJ.

J Endocr Soc. 2018 Oct 11;2(12):1381-1394. doi: 10.1210/js.2018-00170. eCollection 2018 Dec 1.

23.

Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Mar;38(13):2436. doi: 10.1038/s41388-018-0587-3.

PMID:
30510231
24.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

25.

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.

Carabet LA, Lallous N, Leblanc E, Ban F, Morin H, Lawn S, Ghaidi F, Lee J, Mills IG, Gleave ME, Rennie PS, Cherkasov A.

Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.

PMID:
30326371
26.

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.

Garrido MF, Martin NJ, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A.

Clin Cancer Res. 2019 Jan 15;25(2):710-723. doi: 10.1158/1078-0432.CCR-18-0704. Epub 2018 Oct 15.

PMID:
30322877
27.

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.

Zhang Y, Zheng D, Zhou T, Song H, Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann M, Gleave M, Han H, Xu F, Liao W, Wang H, Li W.

Nat Commun. 2018 Oct 4;9(1):4080. doi: 10.1038/s41467-018-06177-2.

28.

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.

Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K.

Eur Urol. 2019 Jan;75(1):44-60. doi: 10.1016/j.eururo.2018.07.027. Epub 2018 Oct 2.

PMID:
30286948
29.

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models.

Deb S, Pham S, Ming DS, Chin MY, Adomat H, Hurtado-Coll A, Gleave ME, Guns EST.

Cancers (Basel). 2018 Sep 20;10(10). pii: E343. doi: 10.3390/cancers10100343.

30.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

31.

A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Feb;38(7):913-934. doi: 10.1038/s41388-018-0488-5. Epub 2018 Sep 7. Erratum in: Oncogene. 2018 Dec 3;:.

32.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

PMID:
30165429
33.

SRRM4 gene expression correlates with neuroendocrine prostate cancer.

Li Y, Zhang Q, Lovnicki J, Chen R, Fazli L, Wang Y, Gleave M, Huang J, Dong X.

Prostate. 2019 Jan;79(1):96-104. doi: 10.1002/pros.23715. Epub 2018 Aug 28.

PMID:
30155992
34.

Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Ghavimi S, Abdi H, Waterhouse J, Savdie R, Chang S, Harris A, Machan L, Gleave M, So AI, Goldenberg L, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):270-275. doi: 10.4859/cuaj.4859. Epub 2018 Apr 6.

35.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
36.

A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B.

Bosc D, Vezenkov L, Bortnik S, An J, Xu J, Choutka C, Hannigan AM, Kovacic S, Loo S, Clark PGK, Chen G, Guay-Ross RN, Yang K, Dragowska WH, Zhang F, Go NE, Leung A, Honson NS, Pfeifer TA, Gleave M, Bally M, Jones SJ, Gorski SM, Young RN.

Sci Rep. 2018 Aug 3;8(1):11653. doi: 10.1038/s41598-018-29900-x.

37.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

38.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ.

J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9.

39.

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. [Epub ahead of print]

40.

Long term deficiency of vitamin D in germ cell testicular cancer survivors.

Nappi L, Ottaviano M, Rescigno P, Fazli L, Gleave ME, Damiano V, De Placido S, Palmieri G.

Oncotarget. 2018 Apr 20;9(30):21078-21085. doi: 10.18632/oncotarget.24925. eCollection 2018 Apr 20.

41.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

42.

Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.

Fan L, Zhang F, Xu S, Cui X, Hussain A, Fazli L, Gleave M, Dong X, Qi J.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):E4584-E4593. doi: 10.1073/pnas.1802415115. Epub 2018 Apr 30.

43.

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A.

Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.

44.

Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Ghavimi S, Abdi H, Waterhouse J, Savdie R, Chang S, Harris A, Machan L, Gleave M, So A, Goldenberg L, Black PC.

Can Urol Assoc J. 2018 Apr 6. doi: 10.5489/cuaj.4859. [Epub ahead of print]

PMID:
29629864
45.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2019 Jul;25(3):979-986. doi: 10.1007/s12253-018-0408-6. Epub 2018 Apr 6.

PMID:
29623528
46.

Co-targeting driver pathways in prostate cancer: two birds with one stone.

Zoubeidi A, Gleave ME.

EMBO Mol Med. 2018 Apr;10(4). pii: e8928. doi: 10.15252/emmm.201808928. No abstract available.

47.

Molecular model for neuroendocrine prostate cancer progression.

Chen R, Dong X, Gleave M.

BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24. Review.

PMID:
29569310
48.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.

49.

The impact of time to metastasis on overall survival in patients with prostate cancer.

Frees S, Akamatsu S, Bidnur S, Khalaf D, Chavez-Munoz C, Struss W, Eigl BJ, Gleave M, Chi KN, So A.

World J Urol. 2018 Jul;36(7):1039-1046. doi: 10.1007/s00345-018-2236-4. Epub 2018 Feb 27.

PMID:
29488095
50.

Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.

Supplemental Content

Loading ...
Support Center